AI drug discovery venture that takes on the challenge of overcoming “unmet medical needs, SOCIUM Inc.’s paper was published in The Journal of Biomedical Research

SOCIUM Inc. (Head office: Chuo-ku, Tokyo; Katsuhisa Horimoto, CEO; after this “SOCIUM”)
We are pleased to announce that our paper on the phosphorylation analysis project has been published in The Journal of Biomedical Research.

Our company and the Nanjing Medical University School of Pharmacy (Dean Prof. Feng Han, Prof. Dongyin Chen) #1 have been selected for the “Japan-China Collaboration Project #2” (2nd round) supported by the Japan International Cooperation Agency (JICA) and implemented by the Ministry of Science and Technology of the People’s Republic of China. This paper is an achievement of that joint project.

Katsuhisa Horimoto, Yuki Suyama, Tadamasa Sasaki, Kazuhiko Fukui, Lili Feng, Meiling Sun, Yamin Tang, Yixuan Zhang, Dongyin Chen, Feng Han. Phosphorylated protein chip combined with artificial intelligence tools for precise drug screening. The Journal of Biomedical Research, 2024, 38(3): 195-205. DOI: 10.7555/JBR.37.20230082

This paper has been accepted as a cover article of a journal, and an illustration of the research is on the cover of the journal.
http://www.jbr-pub.org.cn/index.htm

In addition, this paper is the second academic result of the joint project, the first being the following paper.

Lili Feng, Xiang Chen, Gang Sheng, Yingchun Li, Yingying Li, Yixuan Zhang, Kun Yao, Zhouyue Wu, Rong Zhang, Takayuki Kiboku, Atsushi Kawasaki, Katsuhisa Horimoto, Yamin Tang, Meiling Sun, Feng Han, and Dongyin Chen. Synthesis and Bioevaluation of 3-(Arylmethylene)indole Derivatives: Discovery of a Novel ALK Modulator with Antiglioblastoma Activities. J. Med. Chem. 2023, 66, 21, 14609–14622. https://doi.org/10.1021/acs.jmedchem.3c01090

For inquiries regarding this matter, please contact,
contact@socium.co.jp or https://socium.co.jp/contact/

#1 Nanjing Medical University
Founded in 1934 as Jiangsu Provincial Medical Academy, it was renamed Nanjing Medical Academy in 1957 and Nanjing Medical University in 1993. It is one of the leading medical universities in East China with a history of more than 80 years.
https://spc.jst.go.jp/univorg/university/u0231.html

#2 The Japan-China Cooperation Project of the Ministry of Science and Technology of the People’s Republic of China
This project is one of the private sector partnership projects with the People’s Republic of China supported by JICA from FY2019. It supports Japanese companies in expanding sales channels to China for products (technologies) that have already been established and proven in Japan, through joint research with Chinese partners (research institutes, universities, etc.) and demonstration projects in China in a limited number of fields.
https://www.jica.go.jp/overseas/china/others/pr/index.html

【Phosphorylation Pathway Analysis】
Phosphorylation Pathway Analysis Phospho-Totum (Patent No. 6884389) is the world’s first system to comprehensively analyze phosphorylation status in cells. For 1,471 protein species (substrates) spotted on a glass plate (array), phosphorylation by tyrosine kinases in cell or tissue lysate can be measured. The measurements are seamlessly input into a computational system, which estimates the changes in phosphorylation of each substrate, the activity of intracellular kinases and that of the 231 signaling pathways that the 1,471 substrates comprise.

【SOCIUM Inc.】
SOCIUM Inc. is a drug discovery venture company that discovers first-in-class small molecule compounds. With the vision of “medicine for the unmedicated and medicine for the unmedicated,” the company is committed to overcoming unmet medical needs of patients suffering from diseases. Using its proprietary AI drug discovery platforms Compound-Eyes™, Drug Saver™, and Cyber-Drug-Discovery™, the company searches for novel drug targets and elucidates mechanisms of action based on molecular information such as gene expression, without being limited to conventional pharmacological targets. We are currently working to discover novel drug targets and elucidate their mechanisms of action based on molecular information such as gene expression. Currently, the company’s development portfolio includes oncology and intractable/rare diseases.
For more information, please visit SOCIUM Inc.’s website at https://socium.co.jp/

For inquiries regarding this matter, please contact
SOCIUM Inc.
5th, 6th, and 7th floors of Waterfront Center Annex, National Institute of Advanced Industrial Science and Technology (AIST)
2-4-7 Aomi, Koto-ku, Tokyo 1350064
https://socium.co.jp/
E-mail: contact@socium.co.jp